Transition Paxlovid and Comirnaty to traditional commercial markets in the U.S
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Aug 2023
- Due
- 31 Dec 2023
- Delivered
- November 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“anticipated transition to traditional commercial markets in the U.S. in the second half of 2023”
What we found
Evidence strength A What the grades mean
Pfizer successfully transitioned both Paxlovid and Comirnaty to the U.S. commercial market within the second half of 2023.
-
A Pfizer Inc. 8-K filed 2024-01-30
“Fourth-quarter 2023 Comirnaty(1) revenues declined $6.1 billion, or 54%, operationally compared with the prior-year quarter, largely driven by lower U.S. government contracted deliveries following the transition to traditional U.S. commercial market sales, which began in September 2023” ✓ confirmed on the page
-
A Pfizer Inc. 10-Q filed 2024-05-08
“On October 13, 2023, we announced an amended agreement with the U.S. government, which facilitated the transition of Paxlovid to traditional commercial markets in the U.S. in November 2023” ✓ confirmed on the page
Market reaction: the shares moved -0.3% against the S&P 500 over the three sessions around the disclosure (29 Jan 2024 to 1 Feb 2024). What this measures
Checked 5 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Transition
- Deliverable
- Paxlovid and Comirnaty commercial transition
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Pfizer Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-PFE-004701 · Corrections policy